Abstract
Gastrointestinal cancers (GICs) remain the most diagnosed cancers and accounted for the highest cancer‐related death globally. The prognosis and treatment outcomes of many GICs are poor because most of the cases are diagnosed in advanced metastatic stages. This is primarily attributed to the deficiency of effective and reliable early diagnostic biomarkers. The existing biomarkers for GICs diagnosis exhibited inadequate specificity and sensitivity. To improve the early diagnosis of GICs, biomarkers with higher specificity and sensitivity are warranted. Proteomics study and its functional analysis focus on elucidating physiological and biological functions of unknown or annotated proteins and deciphering cellular mechanisms at molecular levels. In addition, quantitative analysis of translational proteomics is a promising approach in enhancing the early identification and proper management of GICs. In this review, we focus on the advances in mass spectrometry along with the quantitative and functional analysis of proteomics data that contributes to the establishment of biomarkers for GICs including, colorectal, gastric, hepatocellular, pancreatic, and esophageal cancer. We also discuss the future challenges in the validation of proteomics‐based biomarkers for their translation into clinics.
Original language | English |
---|---|
Article number | 973 |
Journal | Cells |
Volume | 11 |
Issue number | 6 |
DOIs | |
Publication status | Published - 11 Mar 2022 |
Keywords
- Biomarkers
- Gastrointestinal cancer
- Mass spectrometry
- Multi‐omics
- Proteomics
ASJC Scopus subject areas
- General Biochemistry,Genetics and Molecular Biology